Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
6
×
Tags
biotech
clinical trials
life sciences
national
6
×
national blog main
national top stories
novartis
zolgensma
6
×
gene therapy
new york top stories
san francisco top stories
biogen
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
fda
indiana blog main
indiana top stories
new york blog main
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
avexis
bristol-myers squibb
glaxosmithkline
abbvie
amgen
brian kaspar
cancer
What
roundup
bio
news
biotech
drug
fda
nash
new
therapy
topped
access
according
advanced
akcea
america
approval
approved
atrophy
august
biogen
biogen’s
biopharmaceutical
busy
capacity
car
cases
cell
centers
cigarettes
companies
consolidation
continues
control
convo
convoluted
crispr
daily
days
deaths
decisions
Language
unset
Current search:
zolgensma
×
photo
×
national
×
@xconomy.com
3 years ago
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
@xconomy.com
4 years ago
CRISPR, CAR-T, Consolidation: Top Advanced Therapy Milestones of 2019
@xconomy.com
4 years ago
Biotech Roundup: Vaping Toll Rises, NASH News, Akcea Shakeup & More
@xconomy.com
4 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com
5 years ago
Bio Roundup: Head and Spine Previews, Biogen Moves, IPO Dreams & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More